Streptococcal toxins: role in pathogenesis and disease

TC Barnett, JN Cole, T Rivera‐Hernandez… - Cellular …, 2015 - Wiley Online Library
Summary Group A Streptococcus (Streptococcus pyogenes), group B Streptococcus
(Streptococcus agalactiae) and Streptococcus pneumoniae (pneumococcus) are host …

The epithelial sodium channel—An underestimated drug target

R Lemmens-Gruber, S Tzotzos - International Journal of Molecular …, 2023 - mdpi.com
Epithelial sodium channels (ENaC) are part of a complex network of interacting biochemical
pathways and as such are involved in several disease states. Dependent on site and type of …

Modulation of innate immunity in airway epithelium for host-directed therapy

IT Myszor, GH Gudmundsson - Frontiers in Immunology, 2023 - frontiersin.org
Innate immunity of the mucosal surfaces provides the first-line defense from invading
pathogens and pollutants conferring protection from the external environment. Innate …

Pneumococcal pneumolysin induces DNA damage and cell cycle arrest

P Rai, F He, J Kwang, BP Engelward, VTK Chow - Scientific reports, 2016 - nature.com
Streptococcus pneumoniae produces pneumolysin toxin as a key virulence factor against
host cells. Pneumolysin is a cholesterol-dependent cytolysin (CDC) toxin that forms lytic …

CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial

PF Laterre, G Colin, PF Dequin, T Dugernier… - The Lancet Infectious …, 2019 - thelancet.com
Background Severe community-acquired pneumonia caused by Streptococcus pneumoniae
is associated with high morbidity and mortality rates. CAL02, a novel antitoxin agent with an …

Pneumolysin as a target for new therapies against pneumococcal infections: A systematic review

MD Cima Cabal, F Molina, JI López-Sánchez… - Plos one, 2023 - journals.plos.org
Background This systematic review evaluates pneumolysin (PLY) as a target for new
treatments against pneumococcal infections. Pneumolysin is one of the main virulence …

Pharmacological targeting of pore-forming toxins as adjunctive therapy for invasive bacterial infection

T Escajadillo, V Nizet - Toxins, 2018 - mdpi.com
For many of the most important human bacterial infections, invasive disease severity is
fueled by the cell damaging and pro-inflammatory effects of secreted pore-forming toxins …

Hsp70 suppresses mitochondrial reactive oxygen species and preserves pulmonary microvascular barrier integrity following exposure to bacterial toxins

X Li, Y Yu, B Gorshkov, S Haigh, Z Bordan… - Frontiers in …, 2018 - frontiersin.org
Pneumonia is a leading cause of death in children and the elderly worldwide, accounting for
15% of all deaths of children under 5 years old. Streptococcus pneumoniae is a common …

Microvesicles released from pneumolysin-stimulated lung epithelial cells carry mitochondrial cargo and suppress neutrophil oxidative burst

E Letsiou, LG Teixeira Alves, D Fatykhova, M Felten… - Scientific Reports, 2021 - nature.com
Microvesicles (MVs) are cell-derived extracellular vesicles that have emerged as markers
and mediators of acute lung injury (ALI). One of the most common pathogens in pneumonia …

[HTML][HTML] Therapeutic potential of kaempferol on Streptococcus pneumoniae infection

L Xu, J Fang, D Ou, J Xu, X Deng, G Chi, H Feng… - Microbes and …, 2023 - Elsevier
Co-infections with pathogens and secondary bacterial infections play significant roles during
the pandemic coronavirus disease 2019 (COVID-19) pathogenetic process, caused by …